These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 4920729)

  • 1. L-DOPA, catecholamines, and behavior: a clinical and biochemical study in depressed patients.
    Goodwin FK; Murphy DL; Brodie HK; Bunney WE
    Biol Psychiatry; 1970 Oct; 2(4):341-66. PubMed ID: 4920729
    [No Abstract]   [Full Text] [Related]  

  • 2. L-dopa, behavioral activation and psychopathology.
    Murphy DL
    Res Publ Assoc Res Nerv Ment Dis; 1972; 50():472-93. PubMed ID: 4627219
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cerebral and peripheral L-dopa uptake in patients with parkinsonian, depressive or manic syndromes administered L-dopa by perfusion combined or not with a decarboxylase inhibitor. Pharmacological effects].
    Geissbuhler F; Eisenring JJ; Friedli P; Bartholini G; Tissot R
    Encephale; 1972; 61(2):127-48. PubMed ID: 4634903
    [No Abstract]   [Full Text] [Related]  

  • 4. Behavioral effects of l-dopa in man.
    Goodwin FK
    Semin Psychiatry; 1971 Nov; 3(4):477-92. PubMed ID: 5173049
    [No Abstract]   [Full Text] [Related]  

  • 5. [10 years of L-DOPA therapy of Parkinson's syndrome].
    Birkmayer W
    Wien Klin Wochenschr; 1971 Apr; 83(13):221-7. PubMed ID: 4254333
    [No Abstract]   [Full Text] [Related]  

  • 6. [Modifications of catecholamine metabolism under the effect of a decarboxylase inhibitor associated with L-dopa and desipramine in patients with depressive and parkinsonian syndromes].
    Geissbuhler F; Bartholini G; Gaillard JM; Tissot R
    Encephale; 1971; 60(3):189-209. PubMed ID: 5119348
    [No Abstract]   [Full Text] [Related]  

  • 7. [Therapy of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor (Ro 4-4602). Course in 71 patients].
    Ferel D
    Schweiz Med Wochenschr; 1972 Jan; 102(3):88-94. PubMed ID: 4551909
    [No Abstract]   [Full Text] [Related]  

  • 8. L-dopa, dopamine, and hypomania.
    Murphy DL; Goodwin FK; Brodie HK; Bunney WE
    Am J Psychiatry; 1973 Jan; 130(1):79-82. PubMed ID: 4682751
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effect of a decarboxylase inhibitor (Ro 4-4602) in combination with L-dopa on inhibited depressions].
    Matussek N; Benkert O; Schneider K; Otten H; Pohlmeier H
    Arzneimittelforschung; 1970 Jul; 20(7):934-5. PubMed ID: 4918921
    [No Abstract]   [Full Text] [Related]  

  • 10. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
    Andrews CJ; Somerville B
    Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical and animal experiments concerning the function of brain catecholamines.
    Matussek N
    Int Pharmacopsychiatry; 1971; 6(3):170-86. PubMed ID: 4950569
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effect of a decarboxylase inhibitor (Ro 4-4602) and L-dopa on inhibited depressions. II. Experimental psychological studies].
    Pohlmeier H; Schön I; Matussek N
    Arzneimittelforschung; 1970 Jul; 20(7):932-3. PubMed ID: 4918920
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].
    Stammler A; Vielhaber K
    Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct; 40(10):564-8. PubMed ID: 4565521
    [No Abstract]   [Full Text] [Related]  

  • 14. [Biochemical bases for the treatment of Parkinson's syndrome with L-dopa].
    Pletscher A; Bartholini G; Gey KF; Jenni A
    Schweiz Med Wochenschr; 1970 May; 100(19):797-804. PubMed ID: 4924275
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; Bartholini G; Constantinidis J; Eisenring JJ; Geissbühler F; Yanniotis G; de Ajuriaguerra J
    Schweiz Med Wochenschr; 1973 Oct; 103(42):1466-74. PubMed ID: 4750149
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of a selective inhibitor of type A monoamine oxidase--Lilly 51641--on behavior, sleep and circadian rhythms in depressed and schizophrenic patients.
    Carman JS; Gillin JC; Murphy DL; Weinberger DR; Kleinman JE; Bigelow LB; Wyatt RJ
    Commun Psychopharmacol; 1978; 2(6):513-23. PubMed ID: 371909
    [No Abstract]   [Full Text] [Related]  

  • 17. [Disturbances of catecholamine metabolism (with special reference to dopamine) in the Parkinsonian syndrome].
    Tissot R
    Presse Med (1893); 1969 Apr; 77(17):617-8. PubMed ID: 5785080
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association].
    Wajsbort J; Hemli JA; Alfandary I; Yahel M; Siegfried J
    Wien Med Wochenschr; 1971 Oct; 121(42):741-5. PubMed ID: 5115985
    [No Abstract]   [Full Text] [Related]  

  • 19. Photic evoked cortical potentials: interaction of reserpine, monoamine oxidase inhibition, and DOPA.
    Sabelli HC; Giardina WJ; Bartizal F
    Biol Psychiatry; 1971; 3(3):273-80. PubMed ID: 5163812
    [No Abstract]   [Full Text] [Related]  

  • 20. The serotonin-catecholamine-dream bicycle: a clinical study.
    Wyatt RJ
    Biol Psychiatry; 1972 Aug; 5(1):33-64. PubMed ID: 4402884
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.